ASTH Stock Forecast & Price Target

Astrana Health is viewed positively because its value-based, full-delegation model and proprietary Care Enablement platform help it manage medical trend, coordinate care, and capture more economics as members shift into higher-risk arrangements. Its fundamentals look strong: in PY 2024 all 8 ACOs delivered shared savings, generating $120.4M in gross shared savings and reaching 100,000 Medicare beneficiaries, while 1Q:26 core medical trend was about 4% and G&A fell to 6.4% of revenue. The outlook is further supported by a favorable 2027 MA rate environment, expected revenue and EBITDA margin expansion, and a valuation that still appears discounted versus peers.

Astrana Health is facing a fragile fundamental setup because the negative organic-growth narrative is difficult to dismiss: Glasshouse noted combined 2025 pro forma revenue declined 3.5%, and GAAP net income was only $1.2M, while the 2025 Prospect acquisition still appears to be working through distressed operations and contracting issues. Although management says the September 22 cybersecurity incident is unlikely to be material, it highlights operational and administrative risk in a highly regulated business that depends on secure credentialing, prior authorizations, and claims administration. The company is also exposed to payer, reimbursement, and Medicaid headwinds, including a projected 10% to 12% enrollment decline this year, about 150 bps of margin pressure, and heavy debt that may constrain investment and expansion.